These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

647 related items for PubMed ID: 22435944

  • 1. Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type 2 diabetes mellitus: adjusting for treatment changes using a marginal structural proportional hazards model and a rank-preserving structural failure time model.
    Shinozaki T, Matsuyama Y, Iimuro S, Umegaki H, Sakurai T, Araki A, Ohashi Y, Ito H, Japanese Elderly Diabetes Intervention Trial Research Group.
    Geriatr Gerontol Int; 2012 Apr; 12 Suppl 1():88-102. PubMed ID: 22435944
    [Abstract] [Full Text] [Related]

  • 2. Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus.
    Krane V, Winkler K, Drechsler C, Lilienthal J, März W, Wanner C, German Diabetes and Dialysis Study Investigators.
    Am J Kidney Dis; 2009 Nov; 54(5):902-11. PubMed ID: 19781835
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).
    Knopp RH, d'Emden M, Smilde JG, Pocock SJ.
    Diabetes Care; 2006 Jul; 29(7):1478-85. PubMed ID: 16801565
    [Abstract] [Full Text] [Related]

  • 4. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
    Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E, German Diabetes and Dialysis Study Investigators.
    N Engl J Med; 2005 Jul 21; 353(3):238-48. PubMed ID: 16034009
    [Abstract] [Full Text] [Related]

  • 5. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
    LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK, Treating to New Targets (TNT) Investigators.
    N Engl J Med; 2005 Apr 07; 352(14):1425-35. PubMed ID: 15755765
    [Abstract] [Full Text] [Related]

  • 6. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
    LaRosa JC, Grundy SM, Kastelein JJ, Kostis JB, Greten H, Treating to New Targets (TNT) Steering Committee and Investigators.
    Am J Cardiol; 2007 Sep 01; 100(5):747-52. PubMed ID: 17719314
    [Abstract] [Full Text] [Related]

  • 7. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.
    Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, Waters D.
    Diabetes Care; 2006 Jun 01; 29(6):1220-6. PubMed ID: 16731999
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study.
    Wenger NK, Lewis SJ, Welty FK, Herrington DM, Bittner V, TNT Steering Committee and Investigators.
    Heart; 2008 Apr 01; 94(4):434-9. PubMed ID: 18070940
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The collaborative atorvastatin diabetes study: preliminary results.
    Owen OG.
    Int J Clin Pract; 2005 Jan 01; 59(1):121-3. PubMed ID: 15707477
    [Abstract] [Full Text] [Related]

  • 14. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.
    Balasubramanian R, Varadharajan S, Kathale A, Nagraj LM, Periyandavar I, Nayak UP, Sharma A, Bolmall C, Baliga VP.
    J Indian Med Assoc; 2008 Jul 01; 106(7):464-7. PubMed ID: 18975505
    [Abstract] [Full Text] [Related]

  • 15. Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
    Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM, Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators.
    N Engl J Med; 2004 Apr 08; 350(15):1495-504. PubMed ID: 15007110
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
    Chu CS, Lee KT, Lee MY, Su HM, Voon WC, Sheu SH, Lai WT.
    Am J Cardiol; 2006 Mar 01; 97(5):646-50. PubMed ID: 16490430
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).
    Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Charlton-Menys V, DeMicco DA, Fuller JH, CARDS Investigators.
    Am J Kidney Dis; 2009 Nov 01; 54(5):810-9. PubMed ID: 19540640
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.